ClinicalTrials.gg

Program

Levomilnacipran

Also written as “Levomilnacipran ER”, “F2695” and “Levomilnacipran Hydrochloride Extended-Release Capsules”.

Its studies are mostly in Depressive Disorder, Major · Depression · Ischemic Stroke, led by 3 companies.

Furthest: phase 4, since Nov 7, 201413 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AbbVie100 open or runningphase 4since Nov 7, 2014Aug 31, 2009none ahead
Pierre Fabre20 open or runningphase 3since Jul 10, 2012Jul 10, 2012none ahead
Zhejiang Huahai Pharmaceutical10 open or runningphase 3since Nov 18, 2025Nov 18, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 31, 2009First studies: 2 phase 3 studies in Depressive Disorder, MajorNew to AbbVieAbbVie · NCT00969709, NCT00969150
  2. Dec 16, 20092 phase 3 studies in Depressive Disorder, MajorAbbVie · NCT01034462, NCT01034267
  3. Mar 10, 2010Phase 3 study in DepressionAbbVie · NCT01085812 · 734 enrolled · United States, Canada
  4. Dec 3, 2010Phase 2 study in Depressive Disorder, MajorAbbVie · NCT01254305 · 262 enrolled · United States
  5. Jun 10, 2011Phase 3 study in Depressive Disorder, MajorAbbVie · NCT01377194 · 568 enrolled · United States, Canada
  6. Jul 10, 2012Pierre Fabre's first study: phase 3 study in Ischemic StrokeNew to Pierre FabrePierre Fabre · NCT01639014 · 532 enrolled · Belgium, Czech Republic, France and more
  7. Sep 19, 2014Phase 1 study in SubjectPierre Fabre · NCT02266966 · 17 enrolled · France
  8. Nov 7, 2014Phase 4 study in Depressive Disorder, MajorAbbVie · NCT02288325 · 644 enrolled · United States
  9. Apr 28, 2015Phase 3 study in Depressive Disorder, MajorAbbVie · NCT02431806 · 552 enrolled · United States, Puerto Rico
  10. Jun 15, 2018Phase 3 study in Depressive Disorder, MajorAbbVie · NCT03569475 · 501 enrolled · United States
  11. Nov 18, 2025Zhejiang Huahai Pharmaceutical's first study: phase 3 study in Depressive Disorder, MajorNew to Zhejiang Huahai PharmaceuticalZhejiang Huahai Pharmaceutical · NCT07253207 · 392 enrolled · China

TargetBeta

“Serotonin transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07253207Depressive Disorder, Major · China3CompletedZhejiang Huahai PharmaceuticalJun 13, 2025392
NCT03569475Depressive Disorder, Major · United States3CompletedAbbVieMar 1, 2021501
NCT02431806Depressive Disorder, Major · United States, Puerto Rico3CompletedAbbVieAug 19, 2019552
NCT02288325Depressive Disorder, Major · United States4CompletedAbbVieSep 16, 2016644
NCT02266966Subject · France1CompletedPierre FabreSep 201417
NCT01639014Ischemic Stroke · Belgium, Czech Republic, France and more3CompletedPierre FabreFeb 2015532
NCT01377194Depressive Disorder, Major · United States, Canada3CompletedAbbVieMar 2012568
NCT01254305Depressive Disorder, Major · United States2CompletedAbbVieJul 2012262
NCT01085812Depression · United States, Canada3CompletedAbbVieOct 2011734
NCT01034462Depressive Disorder, Major · United States3CompletedAbbVieDec 2011442
NCT01034267Depressive Disorder, Major · United States3CompletedAbbVieJun 2012828
NCT00969709Depressive Disorder, Major · United States3CompletedAbbVieMay 2011724
NCT00969150Depressive Disorder, Major · United States3CompletedAbbVieNov 2010362

How it is read

Names in the registry

  • “Levomilnacipran ER”, 11 entries
  • “F2695”, 2 entries
  • “Levomilnacipran Hydrochloride Extended-Release Capsules”, 1 entry
  • “Levomilnacipran”, 1 entry
  • “F2695 SR”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.